Adagene Inc - ADR Stock News
$2.01
2.55%
yesterday
Nasdaq,
Dec 30, 10:00 pm CET
Adagene Inc - ADR Stock News
Neutral
GlobeNewsWire
●
about 2 months ago
- Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4 blockade -
Neutral
GlobeNewsWire
●
3 months ago
SAN DIEGO and SUZHOU, China, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced poster presentations at the upcoming SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024.
Neutral
GlobeNewsWire
●
4 months ago
- Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases for overall response rate (ORR) of 24% (4/17) with ADG126 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab -
Neutral
GlobeNewsWire
●
6 months ago
SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the upcoming ESMO Congress, taking place in Barcelona, Spain, 13-17 September 2024.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
